Navigation Links
KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
Date:7/22/2009

SpringTree Special Opportunities Fund, LP ("SpringTree") announced today its AU$25,500,000 investment in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA Capital acted as the exclusive financial advisor to SpringTree's general partner SpringTree Global Investors, LLC on the transaction. A copy of Prima BioMed Ltd's public announcement follows.

New York (PRWEB) July 22, 2009 -- SpringTree Special Opportunities Fund, LP ("SpringTree") announced today its AU$25,500,000 investment in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA Capital acted as the exclusive financial advisor to SpringTree's general partner SpringTree Global Investors, LLC on the transaction. To view a copy of Prima BioMed Ltd's public announcement please click here http://www.asx.com.au/asxpdf/20090721/pdf/31jn69xw14p8wy.pdf.

About KTA Capital, LLC
KTA Capital is an investment bank headquartered in New York, USA. Its services include international investment banking across a wide range of industries, both in the equity capital and debt markets, as well as M&A advisory. In its business it leverages its relationships with literally hundreds of institutional investors, including hedge funds, mutual funds, private equity funds, venture capital funds, bond funds, mezzanine debt funds, private placement funds, investment advisers, national, regional and international banks, acquisitive industry participants and strategic cornerstone investors, family offices, merchant banks and sovereign wealth funds. KTA Capital is registered as a broker-dealer with the United States Securities and Exchange Commission and is a member of Financial Industry Regulatory Authority, Inc. (" FINRA").

Media Contact:
Eugene Tablis
Tel.: +1 646 707 4177

About SpringTree Global Investors, LLC
SpringTree Global Investors, LLC ( www.springtreegi.com ) is a New York-based asset management company that makes debt and equity investments in public companies around the world with a focus on small-cap and mid-cap companies requiring US$5-US$150 million in debt and/or equity. It invests across a broad range of industries and a wide range of geographies and economic environments.

Contact:
Jeffrey Easton
Tel.: +1 212 255 3552

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2664694.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances
2. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
3. Top CEOs Declare Americas Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership
4. Venture Capitalists to Invest in Promising PA Life Science Companies, Governor Rendell Says
5. Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company
6. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
7. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
8. Merck Serono Launches Strategic Venture Capital Fund
9. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
10. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
11. Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
(Date:10/12/2017)... FL (PRWEB) , ... October ... ... (RPS®) today announces publication of a United States multicenter, prospective clinical study ... use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):